PepVax, Inc.
Immunotherapy Revolutionized
- Stage Product In Development
- Industry Biotechnology
- Location Bethesda, MD, USA
- Currency USD
- Founded February 2013
- Employees 4
- Incorporation Type C-corp
- Website pepvax.co
Company Summary
PepVax, Inc. has developed a novel DNA-based drug delivery platform, called SMARTmid™, for the development of next-generation cell, gene, and immunotherapies, all manufactured inside the patient (Intusic™).
Team
-
President and CEO
Biotechnology entrepreneur with extensive experience in the healthcare and life sciences industry. He has a Master's in Biotechnology from University of Pennsylvania with experience in business development, consulting for start-ups, as well as research in academia and pharmaceutical industry focusing on antibiotics and vaccines.
-
Anton DormerChairman and Chief Scientific Officer
Biotechnology entrepreneur with extensive experience in the healthcare and life sciences industry. He has a Master's in Biotechnology from University of Pennsylvania with experience in business development, consulting for start-ups, as well as research in academia and pharmaceutical industry focusing on antibiotics and vaccines.
-
VP, Bioinformatics
Dr. Daniel Achinko is a research scientist at the University of Yaounde I (UYI), Cameroon. He received his doctorate in Bioinformatics with a focus on Co-parasitic infections, and a Master's in Molecular Parasitology with focus on genotyping the Plasmodium strains of malaria. He is currently a member of the East African Bioinformatic group and the International Society of Computational Biology.
Advisors
-
Sherman RogersLawyerUnconfirmedElton NormanAccountantUnconfirmedPatent Lawyer, Scientific Board Advisor
-
Scientific Advisory Board
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.